The judicious use of real-world data (RWD) could keep a Phase I or II trial from collapsing with the market for oncology treatments for indications non-small cell carcinoma (NSCLC) expected to grow by more than 40% by the end of the decade, bringing competition and opportunity to some markets.
Speaking to a packed room at the 11th Annual Clinical Trials in Oncology conference in Munich GlobalData’s Ophelia Chan outlined that if oncology trials do fail, they fall at some of the earliest hurdles with Phase I and II trials being some of the hardest to recruit patients for.
Go deeper with GlobalData
As part of her presentation Chan detailed a snapshot of the current oncology trials landscape, showing that among the NSCLC, there are currently 4400 ongoing trials in the space with an additional 27 drugs currently in the pre-registration phase. At the same time, the leading countries for diagnoses of NSCLC are Japan, followed closely by China. However, when looking at the rate of trials.
Meanwhile, most trials conducted in the space, largely in areas such as targeted therapies, are carried out largely in the US, leaving only a small number of trials in countries such as Japan, the UK and Italy where the disease is still prevalent. This could be seen as an opportunity for some in a market where competition among a limited population of potential patients can be the undoing of some trials.
Addressing the audience, Chan said: “Low recruitment rates were the primary reason for the failure of NCSLC in 2019, as a result, there could be possible gaps in our patient access or engagement programmes which could be addressed through a targeted outreach programme or through decentralised trials.
“Targeting patients with specific biomarkers could also streamline enrolment, it would increase overall efficacy rates and shorten the trial duration, biomarkers can also help us identify susceptibility to specific adverse events allowing for much more targeted tracking of some patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“Most ongoing and planned NSCLC trials are currently in the Phase I/II stage with America and China leading in recruitment and planning whilst Italy the UK and Japan have the least number of trials and this could indicate less competition compared to the US or Chinese markets.”
Later in her talk Chan similarly echoed the remarks of speakers early in the conference finding that sponsors are unlikely to get the results they are looking for unless they are willing to reduce some of the stress on potential patients so as to keep them involved, arguing that the use of decentralised trials was pivotal to maintaining patient groups.
GlobalData is the parent company of Clinical Trials Arena.
